Phase II trial of SOM230 (pasireotide LAR) in patients with unresectable hepatocellular carcinoma

MLA

Deukwoo Kwon, et al. “Phase II Trial of SOM230 (Pasireotide LAR) in Patients with Unresectable Hepatocellular Carcinoma.” Journal of Hepatocellular Carcinoma, Jan. 2018. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....e02eb58c6a7dceecb5b180c0891fb25d&authtype=sso&custid=ns315887.

APA

Deukwoo Kwon, Niramol Savaraj, Lynn G. Feun, Peter J. Hosein, Stephen P. Richman, Medhi Wangpaichitr, & Ying-Ying Li. (2018). Phase II trial of SOM230 (pasireotide LAR) in patients with unresectable hepatocellular carcinoma. Journal of Hepatocellular Carcinoma.

Chicago

Deukwoo Kwon, Niramol Savaraj, Lynn G. Feun, Peter J. Hosein, Stephen P. Richman, Medhi Wangpaichitr, and Ying-Ying Li. 2018. “Phase II Trial of SOM230 (Pasireotide LAR) in Patients with Unresectable Hepatocellular Carcinoma.” Journal of Hepatocellular Carcinoma, January. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....e02eb58c6a7dceecb5b180c0891fb25d&authtype=sso&custid=ns315887.